Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer.

CONCLUSION: The modification of the FOLFIRI regimen impacted treatment response of mCRC patients. The addition of an antiangiogenic agent, in particular aflibercept, enhanced the clinical benefit and improved survival.
PMID: 30815374 [PubMed]

Source: Clinical Colorectal Cancer - February 23, 2019 Category: Cancer & Oncology Authors: Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F Tags: World J Clin Oncol Source Type: research